Prana candidate reduces Abeta levels
Thursday, 10 July, 2008
Key findings from Prana Biotechnology's [ASX: PBT] preclinical research of its proprietary PBT2 Alzheimer's drug have been published in the prestigious scientific journal Neuron.
The article, "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Abeta," can be viewed on-line by Neuron subscribers.
PBT2 was found to rapidly and profoundly improve cognition in transgenic mice, by substantially reducing the amount of Abeta - amyloid beta, the main constituent of Alzheimer's plaques - in the brain over a nine-month period.
The findings will be presented at the 11th International Conference on Alzheimer's Disease, to be held in Chicago at the end of the month.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
